Recommendations of diagnosis and treatment of giant cell arteritis and polymyalgia rheumatic in China
10.3760/cma.j.cn112138-20221020-00773
- VernacularTitle:风湿性多肌痛和巨细胞动脉炎的诊疗规范
- Author:
Pei WANG
1
;
Xuebing FENG
;
Xingwang DUAN
;
Shengyun LIU
;
Yan ZHAO
Author Information
1. 郑州大学人民医院 河南省人民医院风湿免疫科，郑州 450003
- Keywords:
Polymyalgia rheumatica;
Giant cell arteritis;
Diagnosis;
Treatment;
Prognosis
- From:
Chinese Journal of Internal Medicine
2023;62(3):256-266
- CountryChina
- Language:Chinese
-
Abstract:
Polymyalgia rheumatica (PMR) is a syndrome characterized by pain and morning stiffness in the neck and shoulder and pelvic girdles, as well as raised acute-phase reactants, with or without systemic symptoms, such as fever. Giant cell arteritis (GCA) is a systemic vasculitis of unclear etiology that involves systemic arteries, principally affecting medium- and large-sized arteries with skipped, segmental alterations and granulomatous vasculitis seen on histopathology. In China, epidemiological data describing GCA are still limited; thus, the prevalence might be underestimated. The involvement of vessels in GCA can cause irreversible visual impairment or loss and stroke, which are serious complications. PMR is three times more prevalent than GCA, and other specific diseases should be excluded before the diagnosis is established. PMR symptoms can be present in 40%-60% of patients with GCA. Conversely, GCA can develop in 15% of patients with PMR. Chinese Rheumatology Association, based on the clinical diagnosis and treatment guidelines in 2005, utilizing the experience and guidelines of diagnosis and treatment at home and abroad, formulated this specification to standardize the diagnosis and treatment of GCA and PMR and improve the patient′s prognosis.
